Outcomes	O

The	O
primary	O
outcome	O
was	O
the	O
cumulative	B-PrimaryOutcome
lung	I-PrimaryOutcome
lesion	I-PrimaryOutcome
remission	I-PrimaryOutcome
rate	I-PrimaryOutcome
(	O
lung	B-OutcomeDefinition
CT	I-OutcomeDefinition
examination	I-OutcomeDefinition
indicated	I-OutcomeDefinition
absorption	I-OutcomeDefinition
of	I-OutcomeDefinition
lung	I-OutcomeDefinition
inflammation	I-OutcomeDefinition
)	O
.	O

Secondary	O
outcomes	O
were	O
the	O
improvement	B-SecondaryOutcome
of	I-SecondaryOutcome
clinical	I-SecondaryOutcome
symptoms	I-SecondaryOutcome
(	I-SecondaryOutcome
cough	I-SecondaryOutcome
,	I-SecondaryOutcome
diarrhea	I-SecondaryOutcome
,	I-SecondaryOutcome
dyspnea	I-SecondaryOutcome
,	I-SecondaryOutcome
fever	I-SecondaryOutcome
,	I-SecondaryOutcome
myalgia	I-SecondaryOutcome
)	I-SecondaryOutcome
before	B-TimeFrame
and	I-TimeFrame
after	I-TimeFrame
treatment	I-TimeFrame
;	O
the	B-SecondaryOutcome
changes	I-SecondaryOutcome
of	I-SecondaryOutcome
blood	I-SecondaryOutcome
routine	I-SecondaryOutcome
test	I-SecondaryOutcome
and	I-SecondaryOutcome
IL	I-SecondaryOutcome
-	I-SecondaryOutcome
6	I-SecondaryOutcome
;	O
changes	B-SecondaryOutcome
of	I-SecondaryOutcome
oxygen	I-SecondaryOutcome
therapy	I-SecondaryOutcome
.	O

In	O
addition	O
,	O
we	O
also	O
analyzed	O
the	O
peripheral	B-OtherOutcome
blood	I-OtherOutcome
T	I-OtherOutcome
lymphocyte	I-OtherOutcome
subsets	I-OtherOutcome
(	I-OtherOutcome
count	I-OtherOutcome
and	I-OtherOutcome
proportion	I-OtherOutcome
)	I-OtherOutcome
before	B-TimeFrame
and	I-TimeFrame
after	I-TimeFrame
treatment	I-TimeFrame
.	O

Safety	O
endpoints	O
were	O
the	O
frequencies	B-OtherOutcome
of	I-OtherOutcome
adverse	I-OtherOutcome
events	I-OtherOutcome
in	O
each	O
group	O
.	O

